Pfizer. $3B+ Liquidity. 74 Million Users. Is your intake ready for the Depo-Provera docket?

1. Usage Duration Verification

The science relies on “cumulative dose.” We strictly screen for the “Duration of Use” criteria.

• The 1-Year Rule: Our funnels automatically reject cases where the user only received one or two injections.
• Re-Injection Confirmation: We verify that the claimant received the shot consistently (e.g., every 3 months) for a period of at least one year, aligning with the “5.6x risk” cohort identified in the BMJ study.

2. Specific Injury Validation

Not every headache is a claim.

We filter specifically for Meningioma.

• Diagnosis Confirmation: We screen for claimants who have received a diagnosis of a brain or spinal tumor (meningioma) confirmed by MRI or CT scan.
• Exclusion Logic: We filter out unrelated neurological conditions (e.g., glioblastoma, general migraines without tumor diagnosis) to ensure you are only engaging with compensable plaintiffs.

We verify:

 The Usage: Must be 12+ months (Cumulative Dose).

The Injury: Confirmed Intracranial Meningioma.

The Proof: Imaging verification required.

Usage Duration Verification

The science relies on “cumulative dose.” We strictly screen for the “Duration of Use” criteria.

• The 1-Year Rule: Our funnels automatically reject cases where the user only received one or two injections.
• Re-Injection Confirmation: We verify that the claimant received the shot consistently (e.g., every 3 months) for a period of at least one year, aligning with the “5.6x risk” cohort identified in the BMJ study.
• Usage Duration Verification: Strict screening to ensure the plaintiff used the injection for at least one year (cumulative dose), aligning with the high-risk cohort identified in the March 2024 BMJ study.
• Specific Injury Validation: We do not accept self-reported “brain tumors.” We screen specifically for a diagnosis of Intracranial Meningioma, confirmed by imaging (MRI/CT), while filtering out non-qualifying neurological conditions.
• Timeline & Labeling Checks: Verification that the usage occurred within the actionable window where the alleged failure to warn was most egregious, prior to the FDA’s recent label updates. We verify the timeline. With the FDA finally updating labels in late 2025, we ensure your plaintiffs fall within the actionable window where the failure to warn was most egregious.

We are currently opening inventory for next month’s campaign blocks. If you are looking for plaintiffs that are highly vetted and qualified, let’s connect.

https://calendly.com/mohrmarketing

Ready to build your Depo-Provera inventory?

Contact Mohr Marketing to deploy the Compliance Shield today.

Click Here Get a Custom Quote

Let’s discuss your specific needs and how our Compliance Program, AI Lead Generation Technology, digital marketing, and mass tort cases can help you achieve your growth goals.

www.mohrmktg.com 

Best Wishes,

Mohr Marketing Team

Summary

Article Name

MDL 3140 Alert: The "Silent Risk" in Your 2026 Portfolio

Description

Is your intake ready for the Depo-Provera docket? We are currently opening inventory for next month’s campaign blocks. If you are looking for highly vetted, qualified plaintiffs, let’s connect.

Author

Mohr Marketing Team

Publisher Name

Mohr Marketing, LLC

Publisher Logo